Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6621733 | 0.86 | ACE (0.33) | TSHRACE | |
| SCHEMBL30623589 | 0.79 | GRM2 (0.30) | — | |
| SCHEMBL736492 | 0.79 | CHRNA7 (0.42) | TSHRSIGMAR1 | |
| SCHEMBL30623733 | 0.76 | GRIN1 (0.30) | — | |
| SCHEMBL3224637 | 0.76 | HTR2A (0.35) | — | |
| SCHEMBL12184284 | 0.76 | GABRP (0.36) | TSHR | |
| SCHEMBL30623501 | 0.75 | GRM2 (0.36) | — | |
| SCHEMBL30623663 | 0.75 | GRIN1 (0.33) | TSHR | |
| Hydrochloric Acid SCHEMBL3222393 | 0.75 | HTR2A (0.34) | SIGMAR1 | |
| SCHEMBL30623700 | 0.75 | PIK3CD (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854869-B1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | LILLY CO ELI (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6693109-B2 | SUCH AS ETHYL(3-(4-(AMINOIMINOMETHYL)PHENYL)-1-OXA-2,8-DIAZA-SPIRO(4.5)DEC-2-EN-8 -YL)ACETATE | ELI LILLY AND COMPANY | 2004-02-17 | — | — | US | disclosed |
| US-20030171373-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2003-09-11 | — | — | US | disclosed |
| US-6528534-B2 | Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2002-01-31 | — | — | US | disclosed |
| US-6291469-B1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | ELI LILLY AND COMPANY | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171373-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | AKR1B1 1609/4885TSHR 2392/4885SIGMAR1 4236/4885 |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | AKR1B1 1609/4885TSHR 2392/4885SIGMAR1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.